Qin L, Chavin K D, Ding Y, Favaro J P, Woodward J E, Lin J, Tahara H, Robbins P, Shaked A, Ho D Y
Department of Microbiology, Medical University of South Carolina, Charleston 29425, USA.
Transplantation. 1995 Mar 27;59(6):809-16.
The application of gene transfer techniques to organ transplantation offers the potential for modulation of immunity directly within an allograft without systemic side effects. Expression vectors and promoter elements are important determinants of gene transfer and expression. In this study, various vectors (naked plasmid DNA, retroviral vector, herpes simplex viral vector, and adenoviral vector) with various promoters (RSV-LTR, SV40, MuLV-LTR, HCMVie1) were directly compared to demonstrate the successful gene transfer and expression of beta-galactosidase in murine myoblasts in vitro and within murine heterotopic, nonvascularized cardiac isografts or allografts in vivo. Expression of transferred genes was not toxic to cells and strength of expression varied according to the type of vector. Plasmid DNA was expressed in myocytes, retroviral vector was expressed in the graft infiltrating cells, and herpes simplex and adenoviral vectors were expressed in both myocytes and graft-infiltrating cells. Preliminary studies evaluated the ability of these vectors to deliver immunologically important signals. Allografts injected with pSVTGF-beta 1, a plasmid-encoding transforming growth factor beta 1 (TGF-beta 1) under the control of the SV40 promoter, showed significant prolongation of graft survival of 26.3 +/- 2.5 days compared with 12.6 +/- 1.1 days for untreated allografts, and 12.5 +/- 1.5 days for the allografts injected with control plasmid (P < 0.05). Allografts injected with MFG-vIL-10, a retroviral vector encoding viral interleukin-10 under the control of the MuLV-LTR, showed prolongation of graft survival of 36.7 +/- 1.3 days versus 12.6 +/- 1.1 days for the untreated allograft, and 13.5 +/- 2.0 days for the allografts injected with control retroviral vector (P < 0.001). Both vectors were transcriptionally active in vivo and did not appear to have toxic effects. Gene therapy for transplantation can induce transient expression of immunologically relevant molecules within allografts that impede immune activation while avoiding the systemic toxicity of conventional immunosuppression.
基因转移技术在器官移植中的应用为在同种异体移植物内直接调节免疫反应提供了可能,且无全身副作用。表达载体和启动子元件是基因转移和表达的重要决定因素。在本研究中,直接比较了各种载体(裸质粒DNA、逆转录病毒载体、单纯疱疹病毒载体和腺病毒载体)与各种启动子(劳斯肉瘤病毒长末端重复序列(RSV-LTR)、猴空泡病毒40(SV40)、莫洛尼鼠白血病病毒长末端重复序列(MuLV-LTR)、人巨细胞病毒立即早期启动子(HCMVie1)),以证明β-半乳糖苷酶在体外鼠成肌细胞以及体内鼠异位、非血管化心脏同基因移植物或异基因移植物中成功实现基因转移和表达。转移基因的表达对细胞无毒,且表达强度因载体类型而异。质粒DNA在心肌细胞中表达,逆转录病毒载体在移植物浸润细胞中表达,单纯疱疹病毒载体和腺病毒载体在心肌细胞和移植物浸润细胞中均有表达。初步研究评估了这些载体传递免疫重要信号的能力。注射了pSVTGF-β1(一种在SV40启动子控制下编码转化生长因子β1(TGF-β1)的质粒)的异基因移植物,与未处理的异基因移植物存活时间12.6±1.1天以及注射对照质粒的异基因移植物存活时间12.5±1.5天相比,显示移植物存活时间显著延长至26.3±2.5天(P<0.05)。注射了MFG-vIL-10(一种在MuLV-LTR控制下编码病毒白细胞介素-10的逆转录病毒载体)的异基因移植物,与未处理的异基因移植物存活时间12.6±1.1天以及注射对照逆转录病毒载体的异基因移植物存活时间13.5±2.0天相比,显示移植物存活时间延长至36.7±1.3天(P<0.001)。两种载体在体内均具有转录活性,且似乎没有毒性作用。移植基因治疗可在同种异体移植物内诱导免疫相关分子的瞬时表达,从而阻碍免疫激活,同时避免传统免疫抑制的全身毒性。